Correction to ‘Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis’

IF 2.7 4区医学 Q2 PHARMACOLOGY & PHARMACY

Basic & Clinical Pharmacology & Toxicology Pub Date : 2025-05-14 DOI:10.1111/bcpt.70055

{"title":"Correction to ‘Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis’","authors":"","doi":"10.1111/bcpt.70055","DOIUrl":null,"url":null,"abstract":"\n P.-J. Samuelsen, B. Wettermark, F. Nyberg, M. Hajiebrahimi, “ Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis,” Basic & Clinical Pharmacology & Toxicology 136, no. 2 (2025): e14119, https://doi.org/10.1111/bcpt.14119.\n In the article cited above, several discrepancies occurred between the final author-approved manuscript and the published version.\n Confidence intervals\n \n In-text citation corrections\n \n Reference list corrections\n Reference [32] cited a corrigendum instead of the original guideline. The correct reference is:G. Hindricks, T. Potpara, N. Dagres, et al., “2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC,” European Heart Journal 42, no. 5 (2021): 373–498, https://doi.org/10.1093/eurheartj/ehaa612.In addition, seven references contained minor inaccuracies. The corrected references are listed in the table below:\n These corrections do not affect the conclusions of the article. We apologize for this error.","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 6","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70055","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70055","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

P.-J. Samuelsen, B. Wettermark, F. Nyberg, M. Hajiebrahimi, “ Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis,” Basic & Clinical Pharmacology & Toxicology 136, no. 2 (2025): e14119, https://doi.org/10.1111/bcpt.14119.

In the article cited above, several discrepancies occurred between the final author-approved manuscript and the published version.

Confidence intervals

In-text citation corrections

Reference list corrections

Reference [32] cited a corrigendum instead of the original guideline. The correct reference is:

G. Hindricks, T. Potpara, N. Dagres, et al., “2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC,” European Heart Journal 42, no. 5 (2021): 373–498, https://doi.org/10.1093/eurheartj/ehaa612.

In addition, seven references contained minor inaccuracies. The corrected references are listed in the table below:

These corrections do not affect the conclusions of the article. We apologize for this error.

查看原文本刊更多论文

对“瑞典COVID-19大流行期间抗凝血剂的启动：中断的时间序列分析”的更正

P.-J。Samuelsen， B. Wettermark， F. Nyberg， M. Hajiebrahimi，“瑞典COVID-19大流行期间抗凝血剂的启动：中断时间序列分析”，Basic &；临床药理学；毒理学136号。2 (2025): e14119, https://doi.org/10.1111/bcpt.14119。在上面引用的文章中，作者最终批准的手稿和出版版本之间出现了一些差异。参考文献[32]引用了一个勘误表而不是原始指南。正确的参考是：G。Hindricks， T. Potpara， N. Dagres等人，“2020年ESC房颤诊断和管理指南与欧洲心胸外科协会（EACTS）合作制定：欧洲心脏病学会（ESC）房颤诊断和管理工作组由ESC的欧洲心律协会（EHRA）的特殊贡献制定，”欧洲心脏杂志42，第2期。5 (2021): 373-498, https://doi.org/10.1093/eurheartj/ehaa612.In添加，7个参考文献包含轻微的不准确。修改后的参考文献列于下表：这些修改不影响文章的结论。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Basic & Clinical Pharmacology & Toxicology 医学-毒理学

CiteScore

5.60

自引率

6.50%

发文量

126

审稿时长

1 months

期刊介绍： Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.